JP6960409B2 - プロモーター - Google Patents

プロモーター Download PDF

Info

Publication number
JP6960409B2
JP6960409B2 JP2018545660A JP2018545660A JP6960409B2 JP 6960409 B2 JP6960409 B2 JP 6960409B2 JP 2018545660 A JP2018545660 A JP 2018545660A JP 2018545660 A JP2018545660 A JP 2018545660A JP 6960409 B2 JP6960409 B2 JP 6960409B2
Authority
JP
Japan
Prior art keywords
polynucleotide
nucleic acid
seq
acid molecule
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018545660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019506882A5 (enExample
JP2019506882A (ja
Inventor
ライアン ケイウッド
リチャード パーカー‐マヌエル
ウェイヘン スー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Genetics Ltd
Original Assignee
Oxford Genetics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Genetics Ltd filed Critical Oxford Genetics Ltd
Publication of JP2019506882A publication Critical patent/JP2019506882A/ja
Publication of JP2019506882A5 publication Critical patent/JP2019506882A5/ja
Application granted granted Critical
Publication of JP6960409B2 publication Critical patent/JP6960409B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2018545660A 2016-03-01 2017-02-28 プロモーター Active JP6960409B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1603577.6A GB201603577D0 (en) 2016-03-01 2016-03-01 Promoter
GB1603577.6 2016-03-01
PCT/GB2017/050537 WO2017149292A1 (en) 2016-03-01 2017-02-28 Promoter

Publications (3)

Publication Number Publication Date
JP2019506882A JP2019506882A (ja) 2019-03-14
JP2019506882A5 JP2019506882A5 (enExample) 2020-04-09
JP6960409B2 true JP6960409B2 (ja) 2021-11-05

Family

ID=55807149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018545660A Active JP6960409B2 (ja) 2016-03-01 2017-02-28 プロモーター

Country Status (8)

Country Link
US (1) US10647999B2 (enExample)
EP (2) EP3686282B1 (enExample)
JP (1) JP6960409B2 (enExample)
KR (1) KR102755545B1 (enExample)
AU (1) AU2017225350B2 (enExample)
GB (3) GB201603577D0 (enExample)
SG (1) SG11201806782QA (enExample)
WO (1) WO2017149292A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110892064A (zh) 2017-07-25 2020-03-17 牛津遗传学有限公司 腺病毒载体
CN107630035A (zh) * 2017-09-28 2018-01-26 兰州大学 一种大鼠防御素真核表达载体及其构建方法
GB201800903D0 (en) 2018-01-19 2018-03-07 Oxford Genetics Ltd Vectors
AU2019215152A1 (en) * 2018-02-01 2020-08-20 Homology Medicines, Inc. Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof
GB201901571D0 (en) 2019-02-05 2019-03-27 Oxford Genetics Ltd Inducible AAV sysyem
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
JP2024537896A (ja) 2021-10-18 2024-10-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞
AR127674A1 (es) 2021-10-18 2024-02-21 Regeneron Pharma Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081336A1 (en) * 2006-01-13 2007-07-19 Five Prime Therapeutics, Inc. Mammalian vectors for high-level expression of recombinant proteins
PT1996238T (pt) * 2006-02-28 2016-07-11 Vaxart Inc Vetores adenovíricos quiméricos e arncd como agonista de tlr3
WO2008051854A2 (en) * 2006-10-20 2008-05-02 Trustees Of Boston University A tunable genetic switch for regulating gene expression
EP2097538A4 (en) 2006-12-07 2011-11-30 Switchgear Genomics TRANSCRIPTION REAGULATION ELEMENTS OF BIOLOGICAL PATHS, TOOLS AND METHODS
WO2011034950A1 (en) * 2009-09-16 2011-03-24 Vaxart, Inc. Immunization strategy to prevent h1n1 infection
WO2012112603A1 (en) * 2011-02-14 2012-08-23 University Of Utah Research Foundations Constructs and methods for generating induced pluri potent stem ( ips) cells
BR112013025819A2 (pt) 2011-04-07 2016-12-20 Bayer Crospscience N V promotor específico para semente em algodão
EP2771465A1 (en) * 2011-10-28 2014-09-03 Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University Genetic element that enhances protein translation
HUE026516T2 (en) * 2012-09-24 2016-06-28 Lonza Biologics Plc Expression vectors containing chimeric cytomegalovirus promoter and enhancer sequences
EP3770263A1 (en) 2013-03-12 2021-01-27 AGC Biologics, Inc. Improved recombinant protein expression using a hybrid chef1 promoter
CN104630267B (zh) * 2014-07-17 2017-10-31 清华大学 利用tale转录抑制子在哺乳动物细胞中模块化构建合成基因线路的试剂盒
GB201414130D0 (en) * 2014-08-08 2014-09-24 Agency Science Tech & Res Mutants of the bacteriophage lambda integrase

Also Published As

Publication number Publication date
GB201703224D0 (en) 2017-04-12
KR102755545B1 (ko) 2025-01-17
KR20180132045A (ko) 2018-12-11
AU2017225350B2 (en) 2023-07-20
GB2553170A (en) 2018-02-28
CN109072251A (zh) 2018-12-21
GB2553170B (en) 2020-05-06
GB202002193D0 (en) 2020-04-01
JP2019506882A (ja) 2019-03-14
WO2017149292A1 (en) 2017-09-08
EP3686282A1 (en) 2020-07-29
GB2578859A (en) 2020-05-27
GB2578859B (en) 2020-10-28
EP3423583B1 (en) 2023-05-24
US20190071692A1 (en) 2019-03-07
EP3423583A1 (en) 2019-01-09
GB201603577D0 (en) 2016-04-13
SG11201806782QA (en) 2018-09-27
US10647999B2 (en) 2020-05-12
EP3686282B1 (en) 2024-12-04
AU2017225350A1 (en) 2018-09-06

Similar Documents

Publication Publication Date Title
EP3686282B1 (en) Promoter
CN107502608B (zh) 用于敲除人ALDH2基因的sgRNA、ALDH2基因缺失细胞株的构建方法及应用
JP4489424B2 (ja) 染色体に基くプラットホーム
JP2019193659A (ja) 発現カセット
WO2013063348A1 (en) Genetic element that enhances protein translation
CN118995825A (zh) 一种特异性定量标定白细胞介素15活性的细胞系及其应用
CN118995826A (zh) 一种特异性定量标定白细胞介素7活性的细胞系及其应用
CN110343699A (zh) 用于提高哺乳动物细胞转基因表达的调控序列、表达载体、表达系统及其应用
CN107893085B (zh) 一种可用于孤核受体活性调节剂筛选的双荧光素酶报告基因质粒及其构建与应用
JPWO2004070030A1 (ja) 動物細胞用高発現ベクター
CN112877332A (zh) 一种由双荧光素酶报告基因检测鸡ripk2启动子活性的方法
KR20250166294A (ko) 단리된 뉴클레아제 및 이의 용도
CN104845994B (zh) 一种利用基因组编辑技术实现原位激活基因的表达方法及其应用
HK40034561A (en) Promoter
HK40034561B (en) Promoter
WO2005090562A1 (ja) 軽度の低温により遺伝子の発現を促進させる配列
CN112301054A (zh) 利用k1e噬菌体rna聚合酶和启动子的双质粒系统在真核细胞表达病毒蛋白的方法
CN113584085B (zh) 一种针对悬浮细胞的慢病毒载体及其应用
HK40001212A (en) Promoter
HK40001212B (en) Promoter
Dai et al. Improved fusion protein expression of EGFP via the mutation of both Kozak and the initial ATG codon
CN109468323B (zh) 人工合成的内含子、哺乳动物细胞重组表达载体、哺乳动物宿主细胞、表达方法及其应用
WO2025064834A1 (en) Isolated betacoronavirus ires sequences
CN119662652A (zh) 一种启动子及其应用
CN105219777A (zh) 一种成纤维细胞特异性启动子及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200227

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210414

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210921

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211011

R150 Certificate of patent or registration of utility model

Ref document number: 6960409

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250